PsiOxus Therapeutics announces positive study results of oncolytic vaccine enadenotucirev at 2014 ASCO Annual Meeting
Studies Identify a Phase II Dose and Demonstrate Best in Class Intravenous Delivery Profile Leading to an Expansion of the Clinical Program to New Indications OXFORD, UK and CHICAGO – 3 June, 2014 – PsiOxus Therapeutics, Ltd. (PsiOxus), an award-winning biotechnology company developing innovative, novel treatments for cancer, announced that updates for its on-going international